Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company specializing in rare and orphan diseases, has scheduled its Q2 2025 financial results release for August 7, 2025, before market opening.
The upcoming announcement will feature both financial results for the quarter ending June 30, 2025, and an operational update covering the company's key achievements and recent milestones.
Quoin Pharmaceuticals (NASDAQ: QNRX), un'azienda farmaceutica specializzata in malattie rare e orfane in fase clinica avanzata, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per il 7 agosto 2025, prima dell'apertura del mercato.
L'annuncio includerà sia i risultati finanziari relativi al trimestre terminato il 30 giugno 2025, sia un aggiornamento operativo con i principali traguardi e recenti progressi dell'azienda.
Quoin Pharmaceuticals (NASDAQ: QNRX), una empresa farmacéutica especializada en enfermedades raras y huérfanas en etapa clínica avanzada, ha programado la publicación de sus resultados financieros del segundo trimestre de 2025 para el 7 de agosto de 2025, antes de la apertura del mercado.
El próximo anuncio incluirá tanto los resultados financieros del trimestre que finaliza el 30 de junio de 2025 como una actualización operativa con los principales logros y avances recientes de la compañía.
Quoin Pharmaceuticals (NASDAQ: QNRX)는 희귀 및 고아 질환을 전문으로 하는 후기 임상 단계의 전문 제약회사로, 2025년 8월 7일 2025년 2분기 재무 실적 발표를 시장 개장 전에 예정하고 있습니다.
이번 발표에는 2025년 6월 30일로 종료되는 분기의 재무 실적과 회사의 주요 성과 및 최근 이정표를 포함한 운영 업데이트가 포함될 예정입니다.
Quoin Pharmaceuticals (NASDAQ : QNRX), une société pharmaceutique spécialisée en phase clinique avancée dans les maladies rares et orphelines, a prévu la publication de ses résultats financiers du deuxième trimestre 2025 pour le 7 août 2025, avant l'ouverture des marchés.
L'annonce à venir comprendra à la fois les résultats financiers du trimestre clos le 30 juin 2025 et une mise à jour opérationnelle présentant les principales réalisations et étapes récentes de l'entreprise.
Quoin Pharmaceuticals (NASDAQ: QNRX), ein spezialisiertes Pharmaunternehmen in der späten klinischen Phase mit Fokus auf seltene und vernachlässigte Krankheiten, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für den 7. August 2025 vor Börsenöffnung geplant.
Die bevorstehende Bekanntgabe umfasst sowohl die Finanzergebnisse für das Quartal bis zum 30. Juni 2025 als auch ein operatives Update zu den wichtigsten Erfolgen und jüngsten Meilensteinen des Unternehmens.
- None.
- None.
ASHBURN, Va., July 31, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to release its financial results for the second quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025.
The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, go to: www.quoinpharma.com.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
When will Quoin Pharmaceuticals (QNRX) release its Q2 2025 earnings?
What period will Quoin Pharmaceuticals' Q2 2025 earnings cover?
What will be included in Quoin Pharmaceuticals' Q2 2025 earnings announcement?
What is Quoin Pharmaceuticals' (QNRX) main business focus?
